Research programme: CNS disorder gene therapies - Agilis Biotherapeutics/Gene Therapy Research Institution

Drug Profile

Research programme: CNS disorder gene therapies - Agilis Biotherapeutics/Gene Therapy Research Institution

Alternative Names: AAV based CNS disorder gene therapies - Agilis/GTRI; AAV gene therapies - Agilis/Gene Therapy Research Institution; CNS disorder gene therapies - Agilis/GTRI; CNS disorder gene therapies - GTRI/Agilis; Sf9 baculovirus vector gene therapy - Agilis/GTRI

Latest Information Update: 07 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agilis Biotherapeutics; Gene Therapy Research Institution
  • Developer Agilis Biotherapeutics
  • Class Gene therapies; Neuroprotectants
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research CNS disorders

Most Recent Events

  • 02 Aug 2017 Agilis Biotherapeutics and Gene Therapy Research Institution enter into a joint venture to develop AAV gene therapies using using Sf9 baculovirus and HEK293 mammalian cell systems for the treatment of CNS disorders
  • 02 Aug 2017 Early research in CNS disorders in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top